Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel plus Fulvestrant vs Docetaxel in Metastatic Breast Cancer
NCT02137083Phase 2Completed
- Sponsor
- Fudan University
- Start
- Apr 2014
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fulvestrant in breast cancer (2 arms), sponsored by Fudan University. Primary endpoint: Progression Free Survival at 6 weeks. Started Apr 2014; status: completed.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02137083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02137083.